New hope for kids with rare eye condition: drug combo shows promise
NCT ID NCT07378657
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a systematic approach for treating orbital lymphatic malformation in children aged 1-18. Participants are split into three groups: one gets sclerotherapy (injections to shrink the lesion), one gets the drug sirolimus, and one gets both. The goal is to see if sirolimus is safe and effective at reducing lesion size and improving symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sirolimus
- What this could lead to
- If successful, this could provide a safer, more effective treatment plan for children with orbital lymphatic malformation, reducing symptoms and the need for repeated procedures.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Sirolimus can have side effects like mouth sores and increased infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORBITAL LYMPHATIC MALFORMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ain Shams University
RECRUITINGCairo, Cairo Governorate, 11321, Egypt